COMMENTARY



When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis

Meredith Tyree Polaskey · Heather Woolery-Llloyd · David Osborne · Patrick Burnett · Diane Hanna · Raj Chovatiya D

Received: February 27, 2024 / Accepted: April 5, 2024 / Published online: April 27, 2024 \odot The Author(s) 2024

ABSTRACT

Seborrheic dermatitis (SD) impacts a diverse demographic, with treatment effectiveness and suitability varying across hair types and cultural practices. Available shampoo treatments contain surfactants that compromise hair moisture and integrity as well as requiring frequent use, which may not align with the routines of various hair types and cultural hair care practices. Most available topical foams and gels contain high concentrations of drying alcohols that damage hair color and moisture. Newly US Food and Drug Administration (FDA)-approved roflumilast 0.3% foam presents a significant advancement in the treatment of SD owing to its pH-balanced, residue-free formulation that is suited for all hair types, including patients with curly or coiled hair. It presents a culturally inclusive treatment option that offers effective management of SD while maintaining hair health and respecting diverse hair care needs and practices.

Keywords: Seborrheic dermatitis; Formulation; Foam

M. T. Polaskey · R. Chovatiya (⊠) Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA e-mail: raj.chovatiya@gmail.com

H. Woolery-Llloyd Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, USA

D. Osborne · P. Burnett · D. Hanna Arcutis Biotherapeutics, Inc, Westlake Village, USA

R. Chovatiya

Center for Medical Dermatology and Immunology Research, 3000 N Halsted St, Suite 301, Chicago, IL 60657, USA

Key Summary Points

Seborrheic dermatitis (SD) treatment effectiveness varies across different hair types and cultural practices, necessitating formulations that cater to diverse needs and respect cultural hair care practices.

Commonly used SD treatments, such as shampoos containing surfactants and topical foams with drying alcohols, may compromise hair integrity and color, highlighting the need for innovative formulations.

The recently FDA-approved roflumilast 0.3% foam presents a significant advancement in SD treatment, offering a pH-balanced, residue-free formulation suitable for all hair types and respecting diverse cultural hair care needs.

Embracing cultural inclusivity in SD treatment regimens is crucial for ensuring better patient outcomes, and further research is needed to explore the efficacy and safety of treatments across diverse patient populations, considering a wide range of hair types and cultural dimensions of hair care.

INTRODUCTION

Seborrheic dermatitis (SD) is a common dermatologic condition characterized by erythematous, scaly plaques associated with itch and often presenting with a characteristic distribution, including hair-bearing areas of the scalp, head, and neck. The condition's impact is broad, affecting individuals across a spectrum of hair types. Protective styles, oil treatments, chemical straightening, and personalized washing frequencies, among other diverse hair care practices, can have profound implications for scalp health and SD management [1]. The efficacy of SD treatments relies on their suitability for diverse hair types and histories. Commonly used topical treatments for SD, such as antifungal agents (e.g., ketoconazole, ciclopirox, miconazole), anti-inflammatory compounds (topical corticosteroids such as betamethasone valerate and clobetasol propionate), and keratolytic/humectant substances (e.g., propylene glycol) [2], may not adequately and uniformly serve the full spectrum of patient diversity, such as those belonging to certain racial or ethnic groups and those with curly or coily hair. This gap highlights the pressing need for treatments that are specifically formulated to cater to varied hair needs and respect the cultural context of hair care. This Commentary aims to share insights and perspectives on the current landscape of treatments for SD, encouraging discussion among peers and suggesting directions for future research, grounded in both professional, expert experience and the existing body of evidence.

FORMULATION CHALLENGES IN SD TREATMENTS

Formulating effective SD treatments requires a thoughtful approach to avoid excipients that could weaken hair or alter its color, which can reduce patient adherence and treatment efficacy (Fig. 1). Shampoo treatments require sufficient scalp contact time and are typically recommended for use several times weekly-a frequency incompatible with some hair care routines [3]. Furthermore, these treatments require an acidic pH to prevent hair fiber swelling or unwanted penetration of ingredients into the hair fiber. However, common surfactants like sodium laureth sulfate, found in ciclopirox 1% shampoo and clobetasol propionate 0.05% shampoo, have a pH of 7–9 in 10% solutions and can strip hair of its natural oils and color. This effect is further exacerbated when sodium chloride is added to increase shampoo viscosity [4]. Additionally, cocamide diethanolamine (DEA), a surfactant utilized in 2% ketoconazole shampoo, carries risk of contact dermatitis and is classified by the International Agency for Research on Cancer (IARC) as a Group 1B carcinogen, indicating possible



Fig. 1 Essential elements of topical therapy formulation to consider for seborrheic dermatitis and other inflammatory skin diseases

carcinogenicity to humans [5, 6]. Alternatives like cocamide monoethanolamine (MEA), used in 1% ketoconazole shampoo, are considered safer but may still promote hair dryness and fragility [7]. Furthermore, most topical foams and gels have high concentrations of shortchain alcohols like isopropyl alcohol and ethanol, causing significant drying and stripping of hair color. The presence of these alcohols, alongside the potential irritative and allergenic effects of propylene glycol [8], especially in higher concentrations, necessitates innovative treatments that preserve the integrity of diverse hair types while respecting cultural hair care practices are needed (Table 1).

ADVANCEMENTS WITH ROFLUMILAST FOAM

The recently US Food and Drug Adminstration (FDA)-approved roflumilast 0.3% foam offers a significant advancement in SD treatment, both in efficacy that has been proven highly effective and well tolerated, with substantial clearance of

symptoms in almost 80% of patients and a low incidence of reactions at the site of application [9], and unique elements in formulation (Table 2). The formulation maintains the hair's natural pH and provides moisturization without leaving residue, a common issue with many topical treatments that is particularly problematic for those with textured hair. Central to its formulation is Crodafos CES, a blend of ceteth-10 phosphate, cetearyl phosphate, and cetostearyl alcohol. Crodafos CES is extensively used in the cosmetic industry, with applications ranging from sun protection and baby care products to a range of hair care items including permanent waves, hair colorants, conditioners, and styling aids, with many products tailored for curly and coily hair types [10]. In contrast to other topical treatments, roflumilast foam has a pH near 5.3, aligning with the natural pH of the stratum corneum. This pH optimization enhances drug delivery and bioavailability to inflamed skin by repelling the foam from the negatively charged hair fibers and ensuring the active ingredient is directed towards the scalp

Product	Application frequency	Key formulation concerns
Betamethasone valerate 0.12% foam	Twice daily	60% Ethanol; can cause significant drying and hair fragility
Ketoconazole 1–2% shampoo	Twice weekly	Cocamide diethanolamine (DEA) poses risk of contact dermatitis and is a potential carcinogen; alternatives like cocamide monoethanolamine (MEA) are safer but may dry hair
Ketoconazole 2% foam	Twice daily	58% Ethanol; can cause significant drying and hair fragility
Ketoconazole 2% gel	Once daily	34% Ethanol; less drying but still poses risk to hair integrity
Keratolytic/ humectant solution	Once daily	50% Ethanol; can cause significant drying and hair fragility
Ciclopirox 0.77% gel	Twice daily	Isopropyl alcohol predominant after water, specific concentration not disclosed; can strip hair of natural oils, pH not aligned with hair health

Table 1 Key formulation concerns in topical shampoos,foams, gels, and solutions for seborrheic dermatitistreatment

Table 1 continued

Product	Application frequency	Key formulation concerns
Ciclopirox 1–1.5% shampoo	Three times weekly	Contains sodium laureth sulfate which may compromise hair moisture and color, adding sodium chloride exacerbates this effect
Miconazole 2% solution	Once daily	Contains acetic acid and laureth-4 for pH adjustment and cleansing that can dry and irritate the scalp
Clobetasol propionate 0.05% shampoo	Twice weekly	Contains sodium laureth sulfate which, with a pH of 7–9, can strip hair of its natural oils and color, leading to dryness and potential damage
Propylene glycol 15% solution	Once daily	Can cause irritation and allergic reactions

rather than diffusing into or being adsorbed onto the hair [11].

Roflumilast foam's additional components further contribute to its suitability for all hair types. Diethylene glycol monoethyl ether (commercially known as ethoxydiglycol) provides longer-lasting and more uniform color and prevents split ends formation in hair care products [12]. Hexylene glycol, isopropyl palmitate, and white petrolatum provide moisturization to the hair, with white petrolatum being a preferred moisturizer in certain racial and ethnic groups as well as those with curly or coiled hair. Notably, roflumilast foam is free from high concentrations of alcohols or sulfates, reducing the risk of drying and frizzing. **Table 2** Unique formulation attributes of roflumilast0.3% foam designed for application to hair-bearing areas ofthe scalp

Foam attribute	Benefit
Foam pH 5.3	Does not swell hair fiber— when the hair fiber is swollen by products having a pH value higher than 7, permanent hair color is stripped and unwanted penetration of ingredients into the hair fiber can occur
Foam emulsifier (Crodafos CES) desirable for use on all hair types	Common cosmetic emulsifier used in sun protection, baby care and hair care products tailored for curly and coily hair types
Low levels of the moisturizers hexylene glycol, isopropyl palmitate, and white petrolatum	Provides moisturization to the hair without leaving a residue that could decrease patient dosing compliance for some hair care routines
The foam excipient (DEGEE) that dissolves roflumilast is commonly used in hair care products	The cosmetic-grade solvent ethoxydiglycol provides longer-lasting and more uniform color and prevents split ends formation when used in hair care products

By excluding the use of short chain alcohols and sulfate surfactants, the foam product avoids drying the hair or making the hair more fragile and prone to breakage

Furthermore, its once-daily application regimen ensures consistent delivery of the active ingredient independent of shampooing frequency, making it an ideal treatment for individuals who extend time between washes to preserve protective hairstyles or maintain hair integrity.

CONCLUSION

The treatment of SD necessitates a departure from the one-size-fits-all approach, which fails to accommodate a diversity of hair types and cultural hair care practices. The introduction of topical roflumilast 0.3% foam represents a significant advancement in dermatological care, reflecting a shift toward formulations that are inclusive of all hair types and considerate of various treatment histories such as perms, straightening, coloring, and bleaching. The foam's lightweight consistency ensures easy application and absorption, circumventing heavy buildup that can compromise hair health and styling practices. By embracing cultural inclusivity in treatment regimens, roflumilast foam fosters better adherence and patient-provider collaboration and fills a critical gap in culturally competent SD treatments. Acknowledging this progress, we call for rigorous future research to further explore the efficacy and safety of SD treatments across diverse patient populations, particularly highlighting the importance of considering the wide spectrum of hair types and the cultural dimensions of hair care. This focused inquiry is essential for advancing our understanding and management of seborrheic dermatitis, ensuring that treatment innovations continue to meet the nuanced needs of all patients.

ACKNOWLEDGEMENTS

We thank the participants of the study.

Author Contributions. R Chovatiya had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: R Chovatiya, D Osborne, D Hanna. Acquisition of Data: R Chovatiya, MT Polaskey, HW Lloyd, D Osborne, P Burnett, D Hanna. Analysis and interpretation of data: R Chovatiya, MT Polaskey, HW Lloyd, D Osborne, P Burnett, D Hanna. Drafting of the manuscript: R Chovatiya, MT Polaskey, HW Lloyd, D Osborne, P Burnett, D Hanna. Critical revision of the manuscript for important intellectual content: R Chovatiya, MT Polaskey, HW Lloyd, D Osborne, P Burnett, D Hanna. Statistical analysis: R Chovatiya, MT Polaskey, HW Lloyd, D Osborne, P Burnett, D Hanna.

Funding. The Rapid service fee and Open access fee payment was provided by Arcutis Biotherapeutics.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Conflict of Interest. Meredith Tyree Polaskey has no conflicts to disclose. Heather Woolery-Lloyd has served as a consultant, speaker, and/or investigator for Ortho Dermatologics, L'Oréal, Eli Lillly and Company, Incyte, Pfizer Inc., Galderma, Allergan, Arcutis, Vyne, Eirion, and Regeneron Diane Hanna and Patrick Burnett are employees of Arcutis Biotherapeutics, Inc. Diane Hanna, Patrick Burnett, and David Osborne are shareholders of Arcutis Biotherapeutics, Inc and own stock. Raj Chovatiya has served as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Ethical Approval. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

- Rucker Wright D, Gathers R, Kapke A, Johnson D, Joseph CLM. Hair care practices and their association with scalp and hair disorders in African American girls. J Am Acad Dermatol. 2011;64(2): 253–62. https://doi.org/10.1016/j.jaad.2010.05. 037.
- Dall'oglio F, Nasca MR, Gerbino C, Micali G. An overview of the diagnosis and management of seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2022;15:1537–48. https://doi.org/10.2147/CCID. \$284671.
- Hollins LC, Butt M, Hong J, Taylor SC. Research in brief: survey of hair care practices in various ethnic and racial pediatric populations. Pediatr Dermatol. 2022;39(3):494–6. https://doi.org/10.1111/pde. 14958.
- 4. Howell MC Jr. 17 Dangerous ingredients to avoid in hair care products. https://www.consumernotice.org/products/dangerous-hair-care-ingredients/. Accessed Nov 10, 2023.
- 5. Mertens S, Gilissen L, Goossens A. Allergic contact dermatitis caused by cocamide diethanolamine. Contact Dermatitis. 2016;75(1):20–4. https://doi. org/10.1111/cod.12580.
- International Agency for Research on Cancer. Coconut oil diethanolamine condensate. IARC Monogr Eval Carcinog Risks to Humans. 2013;101: 141–148. https://monographs.iarc.fr/wp-content/ uploads/2018/06/mono101-005.pdf.
- 7. Boyer I, Burnett CL, Bergfeld WF, et al. Safety assessment of PEGs cocamine and related ingredients as used in cosmetics. Int J Toxicol. 2018. https://doi.org/10.1177/1091581818794417.

- 8. McGowan MA, Scheman A, Jacob SE. Propylene glycol in contact dermatitis a systematic review. Dermatitis. 2018;29(1):6–12.
- Zirwas MJ, Draelos ZD, Dubois J, et al. Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial. JAMA Dermatol. 2023;159(6):613–20. https://doi.org/10.1001/ jamadermatol.2023.0846.
- Special Chem. CrodafosTM CES Technical Datasheet. Universal Selector. https://cosmetics.

specialchem.com/product/i-croda-crodafos-ces. Accessed Dec 15, 2023.

- 11. Osborne DW, Berk D. Treatment of skin conditions using high Krafft temperature anionic surfactants. Published online 2021:1–31. https://patents.google. com/patent/AU2021268977A1/en. Accessed 27 Feb 2024.
- 12. UL Solutions. TRANSCUTOL® CG. Prospector. https://www.ulprospector.com/en/na/ PersonalCare/Detail/832/33781/TRANSCUTOL-CG. Accessed Dec 15, 2023.